Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, from 12:25 to 12:55 p.m. ET.

A live webcast of the presentation will be available in the news & press section of the company's website at www.mazetx.com. The webcast will be archived for 90 days following the presentation.

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass^TM, a proprietary, purpose-built platform to leverage genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass^TM, the Company's strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and Twitter.

Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
(650) 850-5080

Media:
Dan Budwick, 1AB
dan@1abmedia.com